CClinicalTrials.gg
RecruitingNCT07533773Updated Jul 17, 2026

Investigating Functional Changes in the Frontotemporal Cortex of Patients With Major Depressive Disorder Following Electroconvulsive Therapy or Magnetic Seizure Therapy Using Functional Near-infrared Spectroscopy (fNIRS)

An interventional study of Electroconvulsive Therapy and Magnetic Seizure Therapy in Major Depressive Disorder (MDD), sponsored by The Second Hospital of Anhui Medical University. Recruiting at 1 site in China. Open to participants aged 12 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by The Second Hospital of Anhui Medical University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
12 Years to 65 Years
Sex
All
01

Study summary

Against the clinical backdrop of the growing global burden of neuropsychiatric disorders, the rapid rise in depression prevalence, and the frequent association of these conditions with cognitive impairment, this study highlights the limitations of current cognitive assessment tools-such as their time-consuming nature and lack of specificity-and underscores the urgent need to develop simple and efficient assessment methods. In terms of treatment, modified electroconvulsive therapy (ECT) and magnetic seizure therapy (MST) are rapidly acting neuromodulation therapies; however, their effects on cognitive function and underlying brain mechanisms remain controversial, and there is a lack of direct comparative studies. Functional near-infrared spectroscopy (fNIRS) technology can non-invasively monitor changes in cerebral hemodynamics, providing a powerful tool for assessing brain function before and after treatment. Therefore, this study aims to combine resting-state and task-based fNIRS with multidimensional cognitive and emotional assessments to systematically compare the effects of ECT and MST on frontal-temporal cerebral hemodynamics. We seek to clarify the differences in brain function regulation between the two treatment modalities and their association with improvements in cognition and mood, with the goal of providing scientific evidence to elucidate the brain mechanisms underlying neurostimulation therapies and optimize individualized treatment plans.

Read the detailed description

The global burden of neuropsychiatric disorders continues to rise. Depression ranks among the leading causes of global disease burden as measured by years lived with disability, and its prevalence increased by more than 36% between 2010 and 2021. Depression manifests not only as core symptoms such as low mood and loss of interest but is also commonly accompanied by cognitive impairment, frequently presenting as declines in executive function, attention, memory, and information processing speed. The severity of these cognitive deficits directly impacts patients' treatment response, recovery of social functioning, and long-term prognosis, making them a key factor limiting patients' return to normal life.

However, there remains a significant gap in the clinical emphasis placed on and assessment of cognitive symptoms. Although existing cognitive assessment tools include subjective self-report questionnaires, individual neuropsychological tests, and battery tests, they generally have limitations: some tools are time-consuming and difficult to adapt to the needs of rapid clinical screening; others lack sufficient clinical evidence and normative data to support their use, resulting in insufficient diagnostic specificity and an inability to accurately match the cognitive impairment characteristics of different neuropsychiatric disorders. Therefore, in conjunction with advancements in neuroscience and technology, the development of simple, efficient, and specific cognitive assessment tools and brain function monitoring methods has become an urgent clinical need.

In the therapeutic field, neurostimulation therapies have gradually emerged as an important complement to pharmacotherapy and cognitive-behavioral therapy. Among these, modified electroconvulsive therapy (ECT) and magnetic seizure therapy (MST) are widely used in the treatment of depression due to their rapid onset of action and significant efficacy. As a classic neurostimulation method, ECT can rapidly alleviate depressive symptoms, particularly suicidal ideation; however, its short-term effects on cognitive function and the underlying brain mechanisms remain controversial. MST, on the other hand, induces localized cortical epileptiform discharges through rapidly changing magnetic fields and is characterized by high targeting precision; however, its safety profile and modulatory effects on brain function require further investigation. Yet, most studies in this field focus on a single treatment modality, lack sufficient comparative analysis of brain functional changes between resting and task states, and, more critically, lack direct comparative studies between ECT and MST.

The development of functional near-infrared spectroscopy (fNIRS) technology provides a powerful tool for addressing these issues. By monitoring changes in the concentrations of oxygenated and deoxygenated hemoglobin, this technology can non-invasively and in real-time reflect regional cerebral blood flow and functional activation levels, making it particularly suitable for assessing dynamic changes in brain function during cognitive tasks. Existing fNIRS studies have confirmed that in patients with depression, the oxygenated hemoglobin response in the prefrontal cortex is significantly lower than that in healthy controls during verbal fluency tasks and working memory N-back tasks, and this abnormality is associated with the severity of depression. During ECT treatment, the oxygenated hemoglobin response in the prefrontal cortex may further decrease; however, the correlation between this change and improvements in mood or cognitive function remains unclear. Furthermore, existing studies have primarily focused on task-based brain function analysis, with limited attention paid to changes in cerebral hemodynamics during rest before and after neurostimulation treatments, and a lack of systematic comparisons between the effects of ECT and MST on frontal-temporal lobe brain function.

Against this backdrop, this study focuses on the effects of ECT and MST on fronto-temporal cerebral hemodynamics. Through a dual-dimensional assessment of both resting-state and task-state conditions, combined with fNIRS technology and multidimensional cognitive and emotional assessment tools, the study aims to clarify the differences in the regulation of fronto-temporal brain function between the two treatment modalities and to reveal the associations between pre- and post-treatment changes in cerebral hemodynamics and improvements in cognitive function and emotional symptoms. The findings will provide new evidence for elucidating the neural mechanisms underlying neurostimulation therapies, offer a scientific basis for optimizing treatment protocols and developing personalized treatment strategies, and ultimately contribute to improving treatment outcomes and patient prognosis for neuropsychiatric disorders.

02

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • Major Depressive Disorder
  • Electroconvulsive Therapy
  • Magnetic Seizure Therapy
  • Functional Near-Infrared Spectroscopy
03

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • A depressive episode diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by two psychiatrists;
  • Meets the treatment criteria for ECT or MST;
  • At least 5 years of education, with no significant hearing or visual impairments;
  • Voluntary participation in this study, with a signed written informed consent form, and willingness to cooperate with the collection of general demographic information, neuropsychological testing, and fNIRS resting-state and task-based data acquisition.

Exclusion criteria

Exclusion Criteria:

  • Co-occurring mental disorders (such as substance use disorders or schizoaffective disorder);
  • Severe physical illness;
  • History of neurological disorders (such as traumatic brain injury or dementia);
  • Low educational attainment;
  • Receipt of ECT or MST treatment within the past six months.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    ECT group

    The patient will undergo at least three sessions of electroconvulsive therapy (ECT).

    Other: Electroconvulsive Therapy

  • Active comparator
    MST group

    The patient will undergo at least three sessions of magnetic seizure therapy (MST).

    Other: Magnetic Seizure Therapy

Interventions

  • OtherElectroconvulsive Therapy

    Electroconvulsive therapy will be administered 2 to 3 times per week according to a standardized protocol. Stimulation parameters-including intensity, target site, number of sessions, and duration-will be individually tailored for each participant based on prior research to ensure targeted and safe delivery within established safety parameters. Treatment will continue until the participant meets the protocol-defined response criteria or completes a maximum of 10 sessions.

  • OtherMagnetic Seizure Therapy

    Magnetic seizure therapy will be administered 2 to 3 times per week according to a standardized protocol. Stimulation parameters-including intensity, target location, number of sessions, and duration-will be individually tailored for each participant based on prior research to ensure targeted and safe delivery within established safety parameters. Treatment will continue until the participant meets the protocol-defined response criteria or completes a maximum of 10 sessions.

05

What researchers measure

Primary outcomes

  1. Change in Hamilton Depression Rating Scale (HAMD) Score

    The HAMD is a clinician-administered depression assessment and consists of 17 items with a total score range from 0 to 54. A higher score indicates a worse outcome.

    Time frame: baseline and immediately after the intervention

  2. Differences in frontal and temporal lobe function during cognitive tasks in patients with depression following seizure therapy.

    Functional near-infrared spectroscopy (fNIRS) was used to measure hemodynamic responses in the frontal and temporal lobes of patients with depression undergoing electroconvulsive therapy (ECT) or magnetic seizure therapy (MST). Test tasks included a category verbal fluency task (VFT) and a Go/No-Go task.

    Time frame: baseline and immediately after the intervention

Secondary outcomes

  1. Self-Rating Depression Scale

    Self-Rating Depression Scale (SDS) comprises 20 items with a total score range of 0-100; higher scores indicate more severe depressive symptoms

    Time frame: Baseline and immediately after intervention

  2. Hamilton Anxiety Rating Scale

    Hamilton Anxiety Rating Scale (HAMA) comprises 14 items with a total score range of 0-56; higher scores indicate more severe anxiety symptoms

    Time frame: Baseline and immediately after intervention

  3. 15-item Somatic Symptom Severity Scale of the Patient Health Questionnaire

    15-item Somatic Symptom Severity Scale of the Patient Health Questionnaire (PHQ-15) comprises 15 items with a total score of 30; higher scores indicate more severe somatization symptoms

    Time frame: Baseline and immediately after intervention

06

Study locations

1 of 1 sites recruiting
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
    Recruiting
07

Registry details

Key details

Study ID
NCT07533773
Lead sponsor
The Second Hospital of Anhui Medical University
Responsible party
Yanghua Tian (President of the First Affiliated Hospital of the University of Science and Technology of China, The Second Hospital of Anhui Medical University) — Principal investigator
First posted
Apr 16, 2026
Start date
Apr 30, 2026
Primary completion
Apr 30, 2029 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Jul 17, 2026

Study contacts

Yanghua Tian
Contact
tianyh@ahmu.edu.cn
+86-13955188448

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion